PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28702823-0 2017 Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Etoposide 0-9 TNF superfamily member 10 Homo sapiens 106-111 28702823-5 2017 In the TRAIL pre-treated cells, ET and DOX induced higher apoptosis, indicating their synergistic effect with TRAIL. Etoposide 32-34 TNF superfamily member 10 Homo sapiens 7-12 28702823-5 2017 In the TRAIL pre-treated cells, ET and DOX induced higher apoptosis, indicating their synergistic effect with TRAIL. Etoposide 32-34 TNF superfamily member 10 Homo sapiens 110-115 22120628-7 2011 Unlike Doxorubicin, Etoposide, Actinomycin D and Wortmannin, a proteasome inhibitor MG132 significantly enhanced TRAIL-induced apoptosis. Etoposide 20-29 TNF superfamily member 10 Homo sapiens 113-118 23124518-4 2012 Although TRAIL-R2 expression increased in IMR-32 cells in response to etoposide treatment, cell death was not increased by concurrent treatment with TRAIL compared with etoposide alone, because the cells lacked caspase 8 expression. Etoposide 70-79 TNF superfamily member 10 Homo sapiens 9-14 23124518-6 2012 Moreover, pretreatment with etoposide increased TRAIL-induced apoptosis in caspase 8 restored IMR-32 cells through activation of a caspase cascade that included caspases 8, 9 and 3. Etoposide 28-37 TNF superfamily member 10 Homo sapiens 48-53 23124518-7 2012 These results indicate that the etoposide-mediated sensitization of neuroblastoma cells to TRAIL is associated with an increase in TRAIL-R2 expression and requires caspase 8 expression. Etoposide 32-41 TNF superfamily member 10 Homo sapiens 91-96 23124518-0 2012 Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL. Etoposide 0-9 TNF superfamily member 10 Homo sapiens 65-70 23124518-2 2012 We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC. Etoposide 43-52 TNF superfamily member 10 Homo sapiens 76-81 23124518-3 2012 In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway. Etoposide 39-48 TNF superfamily member 10 Homo sapiens 185-190 23124518-3 2012 In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway. Etoposide 171-180 TNF superfamily member 10 Homo sapiens 53-58 20877355-10 2010 Only actinomycin D and TRAIL, and etoposide with TRAIL or FasL, enhanced death compared with either agent alone. Etoposide 34-43 TNF superfamily member 10 Homo sapiens 49-54 21514380-6 2011 Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype. Etoposide 107-112 TNF superfamily member 10 Homo sapiens 13-18 21514380-6 2011 Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype. Etoposide 107-112 TNF superfamily member 10 Homo sapiens 214-219 19843632-9 2009 Furthermore, we showed that acquired TRAIL resistance was effectively eliminated by combination with etoposide, doxorubicin, or paclitaxel. Etoposide 101-110 TNF superfamily member 10 Homo sapiens 37-42 20416058-4 2010 RESULTS: We demonstrated that doxorubicin and etoposide markedly sensitized SCLC cells expressing caspase-8 to apoptotic effects of TRAIL. Etoposide 46-55 TNF superfamily member 10 Homo sapiens 132-137 20416058-8 2010 CONCLUSIONS: Our results highlight significant applicability of doxorubicin and etoposide in sensitization of SCLC cells expressing caspase-8 to treatment with TRAIL. Etoposide 80-89 TNF superfamily member 10 Homo sapiens 160-165 20416058-0 2010 Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Etoposide 16-25 TNF superfamily member 10 Homo sapiens 92-97 19834905-9 2009 In a series of in vitro assays, we confirmed the increased toxicity of etoposide and cisplatin to TRAIL resistant HL-60/P1 cells, and adenosine and vidarabine to HL-60/P2, compared with TRAIL-sensitive HL-60 cells. Etoposide 71-80 TNF superfamily member 10 Homo sapiens 98-103 19834905-9 2009 In a series of in vitro assays, we confirmed the increased toxicity of etoposide and cisplatin to TRAIL resistant HL-60/P1 cells, and adenosine and vidarabine to HL-60/P2, compared with TRAIL-sensitive HL-60 cells. Etoposide 71-80 TNF superfamily member 10 Homo sapiens 186-191 17097066-2 2006 The selected TRAIL-resistant cells were cross-resistant to TNF-alpha/cycloheximide but remained sensitive to DNA-damage drugs such as oxaliplatin and etoposide. Etoposide 150-159 TNF superfamily member 10 Homo sapiens 13-18 17441316-8 2007 Cisplatin and etoposide could enhance the sensitivity of TRAIL on SH-SY5Y cells. Etoposide 14-23 TNF superfamily member 10 Homo sapiens 57-62 17881904-5 2007 SP-cells from multiple tumorigenic human cell lines, which are most often resistant to chemotherapeutic agents such as etoposide, cisplatin and 5-FU, are more sensitive to TRAIL than non-SP cells. Etoposide 119-128 TNF superfamily member 10 Homo sapiens 172-177 17431117-5 2007 The TRAIL- and drug-resistant prostate carcinoma PC-3 cell line was treated with CDDP, VP-16, ADR, and vincristine. Etoposide 87-92 TNF superfamily member 10 Homo sapiens 4-9 17441316-12 2007 Cisplatin and etoposide could enhance the killing effect of TRAIL on SH-SY5Y cells. Etoposide 14-23 TNF superfamily member 10 Homo sapiens 60-65 16863850-9 2006 TRAIL sensitivity was enhanced in resistant cell lines by treating with etoposide that concomitantly increased TRAIL-R expression and diminished survivin expression. Etoposide 72-81 TNF superfamily member 10 Homo sapiens 0-5 16923369-10 2006 The early apoptosis rates of the adriamycin /etoposide + IFNgamma+TRAIL groups [(17.9 +/- 3.6)%, (14.8 +/- 3.3)%] were higher than that of the IFNgamma+TRAIL group [(3.9 +/- 1.2)% ](F=26.233, P < 0.01). Etoposide 45-54 TNF superfamily member 10 Homo sapiens 152-157 16863850-9 2006 TRAIL sensitivity was enhanced in resistant cell lines by treating with etoposide that concomitantly increased TRAIL-R expression and diminished survivin expression. Etoposide 72-81 TNF superfamily member 10 Homo sapiens 111-116 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Etoposide 201-210 TNF superfamily member 10 Homo sapiens 151-156 15615731-2 2005 Although many tumor cells are resistant to TRAIL-induced apoptosis alone, they can often be sensitized by co-treatment with DNA-damaging agents such as etoposide. Etoposide 152-161 TNF superfamily member 10 Homo sapiens 43-48 15615731-6 2005 Finally, we show that the extensive caspase 8 cleavage seen during TRAIL-etoposide synergy is a consequence and not a cause of the apoptotic cascade activated downstream of Bid. Etoposide 73-82 TNF superfamily member 10 Homo sapiens 67-72 15368357-1 2004 Jurkat T leukemic cells respond to Etoposide, antineoplastic agent which targets the DNA unwinding enzyme, Topoisomerase II, and TNF-Related-Apoptosis-Inducing-Ligand (TRAIL), 34 kDa transmembrane protein, which displays minimal or no toxicity on normal cells and tissues, not only disclosing the occurrence of apoptosis but also a kind of resistance. Etoposide 35-44 TNF superfamily member 10 Homo sapiens 129-166 15368357-1 2004 Jurkat T leukemic cells respond to Etoposide, antineoplastic agent which targets the DNA unwinding enzyme, Topoisomerase II, and TNF-Related-Apoptosis-Inducing-Ligand (TRAIL), 34 kDa transmembrane protein, which displays minimal or no toxicity on normal cells and tissues, not only disclosing the occurrence of apoptosis but also a kind of resistance. Etoposide 35-44 TNF superfamily member 10 Homo sapiens 168-173 15634660-0 2004 Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death. Etoposide 18-27 TNF superfamily member 10 Homo sapiens 145-200 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Etoposide 201-210 TNF superfamily member 10 Homo sapiens 157-162 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Etoposide 212-216 TNF superfamily member 10 Homo sapiens 151-156 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Etoposide 212-216 TNF superfamily member 10 Homo sapiens 157-162 14500373-4 2003 The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Etoposide 66-75 TNF superfamily member 10 Homo sapiens 137-142 14655759-4 2003 TRAIL also triggered apoptosis in resistant glioma cell lines through the same pathways, but only if the cells were pretreated with chemotherapeutic agents, cisplatin, camptothecin and etoposide. Etoposide 185-194 TNF superfamily member 10 Homo sapiens 0-5 14519653-5 2003 The remaining cell lines and primary cultures were resistant to TRAIL, but cisplatin, chemptothecin, and etoposide sensitized the resistant cell lines and primary cultures to TRAIL-induced apoptosis, which also occurred through the caspase-8-initiated caspase cascade. Etoposide 105-114 TNF superfamily member 10 Homo sapiens 175-180 14500373-4 2003 The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Etoposide 66-75 TNF superfamily member 10 Homo sapiens 162-167 14500373-4 2003 The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Etoposide 66-75 TNF superfamily member 10 Homo sapiens 162-167 12014636-4 2002 RESULTS: Treatment with suboptimal concentrations of etoposide or doxorubicin rendered T-47D cells sensitive to anti-Fas antibody or TRAIL, consistent with Fas and TRAIL-R1 mRNA expression by T-47D cells following drug treatment. Etoposide 53-62 TNF superfamily member 10 Homo sapiens 133-138 12838325-7 2003 Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5. Etoposide 102-111 TNF superfamily member 10 Homo sapiens 139-144 12838325-7 2003 Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5. Etoposide 102-111 TNF superfamily member 10 Homo sapiens 145-150 12618199-0 2003 Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Etoposide 0-9 TNF superfamily member 10 Homo sapiens 69-124 12618199-0 2003 Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Etoposide 0-9 TNF superfamily member 10 Homo sapiens 126-131 12618199-3 2003 In the present study, we examined whether etoposide sensitizes tumor cells with multiple-drug-resistance to TRAIL-induced apoptosis. Etoposide 42-51 TNF superfamily member 10 Homo sapiens 108-113 12618199-7 2003 The density of the TRAIL-receptors (TRAIL-Rs) was not appreciably modulated by the etoposide treatment, suggesting that etoposide targets molecule(s) downstream of the TRAIL-Rs. Etoposide 120-129 TNF superfamily member 10 Homo sapiens 19-24 12618199-7 2003 The density of the TRAIL-receptors (TRAIL-Rs) was not appreciably modulated by the etoposide treatment, suggesting that etoposide targets molecule(s) downstream of the TRAIL-Rs. Etoposide 120-129 TNF superfamily member 10 Homo sapiens 36-41 12618199-7 2003 The density of the TRAIL-receptors (TRAIL-Rs) was not appreciably modulated by the etoposide treatment, suggesting that etoposide targets molecule(s) downstream of the TRAIL-Rs. Etoposide 120-129 TNF superfamily member 10 Homo sapiens 36-41 12127563-4 2002 The results presented here demonstrate that the treatment of Jurkat cells with the apoptosis inducers anti-Fas, TRAIL, staurosporine, and etoposide induces proteolytic fragments of beta-catenin, as did TRAIL and staurosporine in U937 cells. Etoposide 138-147 TNF superfamily member 10 Homo sapiens 202-207 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Etoposide 173-182 TNF superfamily member 10 Homo sapiens 13-18 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Etoposide 173-182 TNF superfamily member 10 Homo sapiens 19-24 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Etoposide 173-182 TNF superfamily member 10 Homo sapiens 67-72 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Etoposide 184-187 TNF superfamily member 10 Homo sapiens 13-18 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Etoposide 184-187 TNF superfamily member 10 Homo sapiens 19-24 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Etoposide 184-187 TNF superfamily member 10 Homo sapiens 67-72 11803469-2 2002 We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Etoposide 56-65 TNF superfamily member 10 Homo sapiens 175-180 10706092-4 2000 Exposure of such cells in vitro to soluble human TRAIL in combination with CDDP or etoposide resulted in synergistic cell death that could be blocked by soluble TRAIL-neutralizing DR5-Fc or the caspase inhibitors, Z-Asp-CH2-DCB and CrmA. Etoposide 83-92 TNF superfamily member 10 Homo sapiens 49-54 11472983-6 2001 TRAIL plus chemotherapy (doxorubicin, cis-platinum, etoposide, or gemcitabine) acted cooperatively to induce apoptosis in mesothelioma cells (M28, REN, VAMT, and MS-1). Etoposide 52-61 TNF superfamily member 10 Homo sapiens 0-5 11090076-6 2000 Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels. Etoposide 39-48 TNF superfamily member 10 Homo sapiens 131-137 10706092-4 2000 Exposure of such cells in vitro to soluble human TRAIL in combination with CDDP or etoposide resulted in synergistic cell death that could be blocked by soluble TRAIL-neutralizing DR5-Fc or the caspase inhibitors, Z-Asp-CH2-DCB and CrmA. Etoposide 83-92 TNF superfamily member 10 Homo sapiens 161-166 11090076-8 2000 These findings indicate that treatment with etoposide, Ara-C, or doxorubicin up-regulates DR5 levels in a p53-independent manner and sensitizes human acute leukemia cells to Apo-2L-induced apoptosis. Etoposide 44-53 TNF superfamily member 10 Homo sapiens 174-180